A small case series suggests a possible benefit.
Most patients with chronic inflammatory demyelinating polyneuropathy (CIDP) respond to treatment with intravenous immunoglobulin (IVIG) or corticosteroids. Nonetheless, some patients have little or no response to either treatment or require high, sustained dosages of these medications to achieve a continuous response. Other second-line immunosuppressive agents such as mycophenolate mofetil are occasionally employed empirically to improve the response or to lower the dosage of corticosteroids or IVIG.
To further our understanding of second-line agents, researchers retrospectively assessed the utility of mycophenolate mofetil in eight patients with CIDP. Two were treatment-naive patients and the other six were on prednisone with or without IVI…